Boehringer Ingelheim, GST partner on equine lameness therapy

First-ever veterinary stem cell medicine recommended for marketing authorization in European Union.

The Boehringer Ingelheim Animal Health Business Unit and Global Stem Cell Technology (GST) have entered into a partnership to enable European veterinarians and horse owners to benefit from a groundbreaking innovation involving a novel therapy based on stem cells to reduce lameness.

Following marketing authorization, Boehringer Ingelheim will exclusively distribute Arti-Cell Forte in the European Union. GST developed Arti-Cell Forte as the first-ever stem cell product in the veterinary arena. The product was recommended for marketing authorization by the European Medicines Agency (EMA) earlier this year, the companies said. 

Arti-Cell Forte is a product candidate of the so-called novel therapies. It is based on horse blood-derived stem cells, which are specially primed. The intended indication is the reduction of mild to moderate recurrent lameness associated with non-septic joint inflammation in horses, the companies said. For convenience, the product shall be offered in a ready-to-use presentation that’s available to the veterinarian whenever it is needed.

Lire la suite:

Laisser un commentaire

Votre adresse e-mail ne sera pas publiée. Les champs obligatoires sont indiqués avec *

Ce site utilise Akismet pour réduire les indésirables. En savoir plus sur comment les données de vos commentaires sont utilisées.

Articles récents

Suivez-nous sur les réseaux sociaux